REGENXBIO Inc. Contracts & Agreements
100 Contracts & Agreements
- Business Finance (10 contracts)
- Business Operations (7)
- Human Resources (20)
- Intellectual Property (33)
- Mergers & Acquisitions (1)
- Real Estate (14)
- Uncategorized (15)
- Sales Agreement, dated as of December 9, 2024, between Leerink Partners LLC and REGENXBIO Inc (Filed With SEC on December 9, 2024)
- Employment Separation Agreement, effective as of September 21, 2024, between the Registrant and Vittal Vasista (Filed With SEC on November 6, 2024)
- Consulting Agreement, effective as of September 16, 2024, between the Registrant and Vittal Vasista (Filed With SEC on November 6, 2024)
- Employment Agreement effective as of July 1, 2024 between the Registrant and Curran Simpson (Filed With SEC on August 1, 2024)
- Consulting and Employment Separation Agreement effective as of July 1, 2024 between the Registrant and Kenneth T. Mills (Filed With SEC on August 1, 2024)
- Underwriting Agreement, dated March 6, 2024, among REGENXBIO Inc. and Morgan Stanley & Co. LLC, Goldman Sachs & Co. LLC, Barclays Capital Inc. and Stifel, Nicolaus & Company,... (Filed With SEC on March 11, 2024)
- Form of Pre-funded Warrant (Filed With SEC on March 11, 2024)
- Form of Employment Agreement for Executive Vice Presidents (Filed With SEC on February 27, 2024)
- ATM Equity OfferingSM Sales Agreement, dated as of September 1, 2023, between BofA Securities, Inc. and REGENXBIO Inc (Filed With SEC on September 1, 2023)
- Compensation Program for Non-Employee Directors (Filed With SEC on August 3, 2022)
- Letter Agreement dated March 21, 2022 between the Company and The Trustees of the University of Pennsylvania (Filed With SEC on May 4, 2022)
- Settlement Agreement and Mutual Release dated November 12, 2021 between the Registrant and Abeona Therapeutics Inc (Filed With SEC on March 1, 2022)
- Description of Securities (Filed With SEC on March 1, 2022)
- Collaboration and License Agreement dated September 10, 2021 between the Company and AbbVie Global Enterprises Ltd (Filed With SEC on November 2, 2021)
- Description of Securities (Filed With SEC on March 1, 2021)
- Form of Restricted Stock Unit Award Agreement for the 2015 Equity Incentive Plan (Filed With SEC on March 1, 2021)
- Form of Stock Option Award Agreement for the 2015 Equity Incentive Plan (Filed With SEC on March 1, 2021)
- Royalty Purchase Agreement dated December 22, 2020 between the Registrant and entities managed by Healthcare Royalty Management, LLC (Filed With SEC on March 1, 2021)
- Underwriting Agreement, dated January 7, 2021, among REGENXBIO Inc. and BofA Securities, Inc., Morgan Stanley & Co. LLC and Barclays Capital Inc., as representatives of the... (Filed With SEC on January 8, 2021)
- Compensation Program for Non-Employee Directors (Filed With SEC on November 4, 2020)
- Fifth Amendment to License Agreement effective September 11, 2020 between the Company and The Trustees of the University of Pennsylvania (Filed With SEC on November 4, 2020)
- Fifth Amendment to Lease dated October 30, 2020 between the Company and ARE-Maryland No. 45, LLC (Filed With SEC on November 4, 2020)
- Third Amendment to Lease dated October 30, 2020 between the Company and ARE-Maryland No. 24, LLC (Filed With SEC on November 4, 2020)
- Description of Securities (Filed With SEC on February 26, 2020)
- First Amendment to License Agreement dated November 4, 2019 between the Registrant and Abeona Therapeutics Inc (Filed With SEC on February 26, 2020)
- Compensation Program for Non-Employee Directors (Filed With SEC on February 26, 2020)
- Second Amendment to Lease dated November 4, 2019 between the Company and ARE-Maryland No. 24, LLC (Filed With SEC on November 5, 2019)
- Compensation Program for Non-Employee Directors (Filed With SEC on August 7, 2019)
- First Amendment to Lease dated May 28, 2019 between REGENXBIO Inc. and DS400OWNER, LLC (Filed With SEC on June 3, 2019)
- Lease dated May 16, 2016 between REGENXBIO Inc. and DS400OWNER, LLC, as successor-in-interest to 400 Madison Holdings, LLC (Filed With SEC on June 3, 2019)
- First Amendment to Lease dated April 23, 2019 between the Company and ARE-Maryland No. 24, LLC (Filed With SEC on May 7, 2019)
- Letter Agreement to Lease dated April 12, 2019 between the Company and ARE-Maryland No. 24, LLC (Filed With SEC on May 7, 2019)
- Fourth Amendment to License Agreement effective April 4, 2019 between the Company and The Trustees of the University of Pennsylvania (Filed With SEC on May 7, 2019)
- Employment Agreement effective April 17, 2019 between the Company and Steve Pakola, M.D (Filed With SEC on May 7, 2019)
- License Agreement dated November 4, 2018 between the Registrant and Abeona Therapeutics Inc (Filed With SEC on February 27, 2019)
- Compensation Program for Non-Employee Directors (Filed With SEC on February 27, 2019)
- Underwriting Agreement, dated August 9, 2018, among REGENXBIO Inc. and Morgan Stanley & Co. LLC, Merrill Lynch, Pierce, Fenner & Smith Incorporated and Barclays Capital Inc., as... (Filed With SEC on August 10, 2018)
- Fourth Amendment to Lease dated April 20, 2018 between the Registrant and BMR-Medical Center Drive LLC (Filed With SEC on May 8, 2018)
- First Amendment to License Agreement dated January 8, 2018 between the Registrant and AveXis, Inc (Filed With SEC on March 6, 2018)
- Separation Agreement and General Release, dated January 26, 2018, between the Company and Faraz Ali (Filed With SEC on February 1, 2018)
- First Amendment to Lease dated November 3, 2017 between the Company and 9600 Blackwell II LLC, as successor in interest to TNREF III 9600 Blackwell, LLC (Filed With SEC on November 8, 2017)
- AGREEMENT AND PLAN OF MERGER by and among: DIMENSION THERAPEUTICS, INC., a Delaware corporation; REGENXBIO INC., a Delaware corporation; and MUDDY CHARLES ACQUISITION CORPORATION,... (Filed With SEC on August 25, 2017)
- Third Amendment to Lease dated July 21, 2017 between the Registrant and BMR-Medical Center Drive LLC (Filed With SEC on August 8, 2017)
- Employment Agreement effective as of March 27, 2017 between the Registrant and Olivier Danos, Ph.D (Filed With SEC on May 9, 2017)
- 3,700,000 Shares REGENXBIO INC. COMMONSTOCK (PAR VALUE $0.0001 PER SHARE) UNDERWRITING AGREEMENT (Filed With SEC on March 24, 2017)
- CONFIDENTIAL TREATMENT REQUESTED FIRST AMENDMENT TO EXCLUSIVE PATENT LICENSE AGREEMENT (EPLA) (Filed With SEC on March 7, 2017)
- [Letterhead of REGENXBIO Inc.] (Filed With SEC on November 9, 2016)
- LEASE AGREEMENT 9600 Blackwell Road Rockville, Maryland TNREF III 9600 BLACKWELL, LLC Landlord and REGENXBIO INC. Tenant DATED: January 28, 2016 INDEX (Filed With SEC on March 3, 2016)
- FIRST AMENDMENT TO LEASE (Filed With SEC on March 3, 2016)
- SECOND AMENDMENT TO LEASE (Filed With SEC on March 3, 2016)
- CONFIDENTIAL TREATMENT REQUESTED LICENSE AGREEMENT (Filed With SEC on September 16, 2015)
- CONFIDENTIAL TREATMENT REQUESTED SECOND AMENDMENT TO LICENSE AGREEMENT (Filed With SEC on September 16, 2015)
- CONFIDENTIAL TREATMENT REQUESTED OPTION AND LICENSE AGREEMENT (Filed With SEC on September 16, 2015)
- CONFIDENTIAL TREATMENT REQUESTED OPTION AND LICENSE AGREEMENT (Filed With SEC on September 15, 2015)
- REGENXBIO INC. 2015 EQUITY INCENTIVE PLAN (AS ADOPTED ON JUNE 17, 2015) REGENXBIO INC. 2015 EQUITY INCENTIVE PLAN (Filed With SEC on September 15, 2015)
- CONFIDENTIAL TREATMENT REQUESTED UNIVERSITY of PENNSYLVANIA License Agreement (Filed With SEC on September 15, 2015)
- CONFIDENTIAL TREATMENT REQUESTED UNIVERSITY of PENNSYLVANIA Second Amendment to License Agreement (Filed With SEC on September 15, 2015)
- CONFIDENTIAL TREATMENT REQUESTED (Filed With SEC on September 15, 2015)
- CONFIDENTIAL TREATMENT REQUESTED LICENSE AGREEMENT (Filed With SEC on September 15, 2015)
- CONFIDENTIAL TREATMENT REQUESTED (Filed With SEC on September 15, 2015)
- CONFIDENTIAL TREATMENT REQUESTED LICENSE AGREEMENT (Filed With SEC on September 15, 2015)
- CONFIDENTIAL TREATMENT REQUESTED AGREEMENT (Filed With SEC on September 15, 2015)
- CONFIDENTIAL TREATMENT REQUESTED LICENSE AGREEMENT (Filed With SEC on September 15, 2015)
- CONFIDENTIAL TREATMENT REQUESTED FIRST AMENDMENT TO LICENSE AGREEMENT (Filed With SEC on September 15, 2015)
- CONFIDENTIAL TREATMENT REQUESTED DEVELOPMENT, MANUFACTURING, AND TESTING STANDARD TERMS AND CONDITIONS (Filed With SEC on September 15, 2015)
- CONFIDENTIAL TREATMENT REQUESTED UNIVERSITY OF MINNESOTA EXCLUSIVE PATENT LICENSE AGREEMENT (Filed With SEC on September 15, 2015)
- CONFIDENTIAL TREATMENT REQUESTED LICENSE AGREEMENT (Filed With SEC on September 15, 2015)
- CONFIDENTIAL TREATMENT REQUESTED LICENSE AGREEMENT (Filed With SEC on September 15, 2015)
- CONFIDENTIAL TREATMENT REQUESTED LICENSE AGREEMENT (Filed With SEC on September 15, 2015)
- REGENXBIO INC. 2015 EMPLOYEE STOCK PURCHASE PLAN (AS ADOPTED ON JUNE 17, 2015) REGENXBIO INC. 2015 EMPLOYEE STOCK PURCHASE PLAN (Filed With SEC on September 8, 2015)
- REGENXBIO INC. 2015 EQUITY INCENTIVE PLAN (AS ADOPTED ON JUNE 17, 2015) REGENXBIO INC. 2015 EQUITY INCENTIVE PLAN (Filed With SEC on September 8, 2015)
- [ ] Shares REGENXBIO INC. COMMONSTOCK (PAR VALUE $0.0001 PER SHARE) UNDERWRITING AGREEMENT (Filed With SEC on September 8, 2015)
- CONFIDENTIAL TREATMENT REQUESTED UNIVERSITY OF MINNESOTA EXCLUSIVE PATENT LICENSE AGREEMENT (Filed With SEC on August 17, 2015)
- AMENDED AND RESTATED INVESTORS RIGHTS AGREEMENT (Filed With SEC on August 17, 2015)
- INDEMNITY AGREEMENT (Filed With SEC on August 17, 2015)
- REGENXBIO Inc. 2014STOCK PLAN ADOPTED ON SEPTEMBER 16, 2014 AMENDED ON JANUARY 8, 2015 AMENDED ON MAY 14, 2015 TABLE OF CONTENTS (Filed With SEC on August 17, 2015)
- REGENXBIO INC. 2015 EQUITY INCENTIVE PLAN (AS ADOPTED ON JUNE 17, 2015) REGENXBIO INC. 2015 EQUITY INCENTIVE PLAN (Filed With SEC on August 17, 2015)
- REGENX BIOSCIENCES, LLC BOARD OF MANAGERS AGREEMENT (Filed With SEC on August 17, 2015)
- REGENXBIO INC. MANAGEMENT CASH INCENTIVE PLAN (AS ADOPTED EFFECTIVE SEPTEMBER , 2015) TABLE OF CONTENTS (Filed With SEC on August 17, 2015)
- CONFIDENTIAL TREATMENT REQUESTED COOPERATION AGREEMENT (Filed With SEC on August 17, 2015)
- CONFIDENTIAL TREATMENT REQUESTED DEVELOPMENT, MANUFACTURING, AND TESTING STANDARD TERMS AND CONDITIONS (Filed With SEC on August 17, 2015)
- LEASE by and between BMR-MEDICAL CENTER DRIVE LLC, aDelaware limited liability company and REGENXBIO INC., a Delawarecorporation Table of Contents (Filed With SEC on August 17, 2015)
- CONFIDENTIAL TREATMENT REQUESTED LICENSE AGREEMENT (Filed With SEC on August 17, 2015)
- REGENXBIO INC. COMPENSATION PROGRAM FOR NON-EMPLOYEE DIRECTORS ADOPTED , 2015 (Filed With SEC on August 17, 2015)
- CONFIDENTIAL TREATMENT REQUESTED UNIVERSITY of PENNSYLVANIA License Agreement (Filed With SEC on August 17, 2015)
- CONFIDENTIAL TREATMENT REQUESTED (Filed With SEC on August 17, 2015)
- CONFIDENTIAL TREATMENT REQUESTED UNIVERSITY of PENNSYLVANIA Second Amendment to License Agreement (Filed With SEC on August 17, 2015)
- CONFIDENTIAL TREATMENT REQUESTED (Filed With SEC on August 17, 2015)
- AMENDMENT TO LICENSE AGREEMENT (Filed With SEC on August 17, 2015)
- CONFIDENTIAL TREATMENT REQUESTED LICENSE AGREEMENT (Filed With SEC on August 17, 2015)
- CONFIDENTIAL TREATMENT REQUESTED (Filed With SEC on August 17, 2015)
- REGENXBIO INC. 2015 EMPLOYEE STOCK PURCHASE PLAN (AS ADOPTED ON JUNE 17, 2015) REGENXBIO INC. 2015 EMPLOYEE STOCK PURCHASE PLAN (Filed With SEC on August 17, 2015)
- CONFIDENTIAL TREATMENT REQUESTED AGREEMENT (Filed With SEC on August 17, 2015)
- CONFIDENTIAL TREATMENT REQUESTED LICENSE AGREEMENT (Filed With SEC on August 17, 2015)
- CONFIDENTIAL TREATMENT REQUESTED FIRST AMENDMENT TO LICENSE AGREEMENT (Filed With SEC on August 17, 2015)
- CONFIDENTIAL TREATMENT REQUESTED SECOND AMENDMENT TO LICENSE AGREEMENT (Filed With SEC on August 17, 2015)
- CONFIDENTIAL TREATMENT REQUESTED OPTION AND LICENSE AGREEMENT (Filed With SEC on August 17, 2015)
- CONFIDENTIAL TREATMENT REQUESTED LICENSE AGREEMENT (Filed With SEC on August 17, 2015)
- CONFIDENTIAL TREATMENT REQUESTED LICENSE AGREEMENT (Filed With SEC on August 17, 2015)
- CONFIDENTIAL TREATMENT REQUESTED LICENSE AGREEMENT (Filed With SEC on August 17, 2015)
